← boardnext 2031-08
BCRX
BioCryst Pharmaceuticalsdistress 1/10 · well-funded / low risk$9.38-1%today-16% from 52w high
Metabolic / Obesity 1
Lead: Hereditary Angioedema
Revenue
pre-revenue
Liquidity
$259M
Runway
—
Shares 1y
+21%
Price & events
+38.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+2.9%
1W
+0.7%
1M
+7.0%
3M
+38.1%
6M
+8.9%
1Y
+25.5%
2Y
-45.7%
5Y
+27.0%
All
Overview
- Market Cap
- $2.38B
- Enterprise Value
- $2.61B
- Volume
- 131.79K
- 52 Week Range
- $6.24 – $11.11
- Total Shares
- 254.16M
- Float Shares
- 221.04M
- Short %
- 19.30%
- % Held by Insiders
- 1.20%
- % Held by Institutions
- 101.38%
- RVOL
- 0.02x
- Beta
- 0.54
Pipeline stages · 3 programs
berotralstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BCX9930
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
avoralstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2031-08 Estimated 50% readout ~2031-10-15 | Phase 3 | berotralstat | Hereditary Angioedema, HAE | — | enrolling by invitation |
| 2026-04-17 | Phase 1 | avoralstat | Diabetic Macular Edema (DME) | 3 | terminated |
| 2025-01-31 | Phase 2 | BCX9930 | Paroxysmal Nocturnal Hemoglobinuria | 28 | terminated |
Catalyst news & presentations · 12
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-05-04partnershipnavenibart · Licensed exclusive European commercialization rights to Neopharmed Gentili for $70M upfront plus up to $275M in milestones.SEC 8-K
- first quarter of 2026trial initiationsecondaryMerger with Astria Therapeutics expected to close.SEC 8-K
- 2026-01-23partnershipCompleted merger with Astria Therapeutics.SEC 8-K
- January 12, 2026 at 1:30 p.m. ETconferencedata presentationsecondaryWebcast presentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- December 12, 2025PDUFAPDUFAORLADEYO (berotralstat) · PDUFA target action date for once-daily ORLADEYO oral granules NDASEC 8-K
- 2025-12-03partnershipEarly termination of HSR waiting period for acquisition of Astria.SEC 8-K
- 2025-10-01partnershipORLADEYO · Completed sale of European ORLADEYO business to Neopharmed Gentili for $250M upfront plus up to $14M milestones.SEC 8-K
- 2025-06-23pdufa extensionORLADEYO (berotralstat) · FDA extended original PDUFA goal date by three months due to major amendment (final reports and formulation data).SEC 8-K
- January 14, 2025 at 6:00 p.m. ETconferencedata presentationsecondaryPresentation at the 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- Tuesday, January 14, 2025 at 6:00 p.m. ETconferencedata presentationsecondaryPresentation at 43rd Annual J.P. Morgan Healthcare Conference.SEC 8-K
- 2024-09-30partnershipRAPIVAB (peramivir injection) · HHS awards up to $69M contract for up to 95,625 doses of RAPIVAB for Strategic National Stockpile; first $13.9M order for 19,125 doses due by Sep 29, 2025SEC 8-K
Approved drugs (3)
- ORLADEYOBEROTRALSTAT DIHYDROCHLORIDE2025 · Prescription
- ORLADEYOBEROTRALSTAT DIHYDROCHLORIDE2020 · Prescription
- RAPIVABPERAMIVIR2014 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+124% upside) · 11 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-06-30HC Wainwright & Co.Buy
- 2026-06-30Cantor FitzgeraldOverweight
- 2026-05-07CitizensMarket Outperform
- 2026-05-07WedbushOutperform
- 2026-05-06NeedhamBuy
Competitors — Hereditary Angioedema
Recent news
- 2026-07-22Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
- 2026-07-22BioCryst to Report Second Quarter 2026 Financial Results on August 5 - GlobeNewswire
- 2026-07-21Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story? - Sahm
- 2026-07-20BioCryst Pharmaceuticals (BCRX) Proxy filing Summary - Quartr
- 2026-07-18BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary - Quartr
- 2026-07-15BioCryst Appoints David W. Jenkins as Chief Scientific Officer - GlobeNewswire
- 2026-07-14BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure - Sahm
- 2026-07-13BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.